Results 231 to 240 of about 136,428 (330)

Glucocorticoids and HPA axis regulation in the stress–obesity connection: A comprehensive overview of biological, physiological and behavioural dimensions

open access: yesClinical Obesity, Volume 15, Issue 2, April 2025.
Summary Chronic stress, characterized by increased long‐term exposure to the glucocorticoid hormone cortisol, is increasingly linked to obesity development. Still, various knowledge gaps persist, including on underlying pathophysiological mechanisms. The aim of the current review is to provide the latest insights on the connection between stress and ...
Robin Lengton   +4 more
wiley   +1 more source

Use of glucagon-like peptide-1 receptor agonists in patients with left ventricular assist devices. [PDF]

open access: yesESC Heart Fail
Ibrahim R   +12 more
europepmc   +1 more source

Development of NAFLD‐Specific Human Liver Organoid Models on a Microengineered Array Chip for Semaglutide Efficacy Evaluation

open access: yesCell Proliferation, EarlyView.
Microporous array organ chips were integrated with commercially available well plates to develop organoid chip platforms, which enable modelling of hepatic physiology and non‐alcoholic fatty liver disease (NAFLD) pathogenesis, as well as evaluation of semaglutide therapeutics. ABSTRACT Progressive non‐alcoholic fatty liver disease (NAFLD) may culminate
Xiao‐yan You   +3 more
wiley   +1 more source

Consumer Food Purchases After Glucagon-Like Peptide-1 Receptor Agonist Initiation.

open access: yesJAMA Netw Open
Sørensen KK   +6 more
europepmc   +1 more source

Efficacy and safety of CT‐868, a novel, fully biased, dual glucagon‐like peptide‐1/glucose‐dependent insulinotropic polypeptide receptor agonist, in type 2 diabetes: A double‐blind, randomized placebo controlled phase 2 trial

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To assess the glycaemic efficacy and safety of CT‐868, a cAMP signal‐biased, dual glucagon‐like peptide‐1/glucose‐dependent insulinotropic polypeptide receptor agonist, in participants with type 2 diabetes (T2D). Materials and Methods This 26‐week (W), phase 2, randomized, double‐blind placebo‐controlled trial enrolled adults with T2D ...
Manu V. Chakravarthy   +10 more
wiley   +1 more source

Burden of long‐term conditions and management of people with overweight and obesity: Data from the United Kingdom primary care cohort of the IMPACT‐O study

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims The multi‐country epIdeMiology landscape PAtient Care paThways of Obesity (IMPACT‐O) retrospective cohort study utilised existing electronic medical records to gather data on overweight and obesity. We report UK data on obesity‐related complications (ORCs) and management strategies.
Kamlesh Khunti   +6 more
wiley   +1 more source

Effect of Glucagon-Like Peptide 1 Receptor Agonists on Patients With Rheumatoid Arthritis. [PDF]

open access: yesACR Open Rheumatol
Kellner DA   +8 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy